Current Research1. Quark Pharmaceuticals and NORDIC are collaborating on an investigational drug trial to evaluate a neuroprotection therapy for acute Non-arteritic Anterior Ischemic Optic Neuropathy (NAION).  The trial is currently enrolling subjects who are 50-80 years old and have had sudden vision loss in one eye within the last 14 days.  The trial is being conducted by Neuro-Ophthalmologists in private practices and in hospitals around the United States. 

Click here if you have experienced recent, sudden vision loss in one eye and would like information on enrolling as a Subject.

Click here if you are an Eye Care Specialist and would like information on referring a patient to this trial.

Sponsor website: http://www.eyeactnow.com/

2. Idiopathic Intracranial Hypertension

NORDIC has concluded a study on Idiopathic Intracranial Hypertension Treatment Trial (IIHTT).  IIH, also called pseudotumor cerebri, is a disorder of elevated intracranial pressure of unknown case. Its incidence is 22.5 new cases each year per 100,000 overweight women of childbearing age; its incidence is rising in parallel with the obesity epidemic. It affects about 100,000 Americans.  Recruitment has concluded for this study. LEARN MORE

Publications 

NORDIC Idiopathic Intracranial Hypertension Study Group

OCT SUBSTUDY: NORDIC IIHTT STUDY GROUP

3. The Pediatric Optic Neuritis Prospective Outcomes Study, a joint collaboration between NORDIC and the Pediatric Eye Disease Investigator Group (PEDIG), is now open to interested sites.  This observational data collection study is funded by the National Eye Institute and will determine our investigators' ability to enroll children with optic neuritis into a research protocol, and help us develop estimates of visual acuity outcomes in these children.  Treatment is at the discretion of the investigator. A small research payment is made to sites for each enrollment and follow up exam completed.  If you are interested in participating, please email pedig@jaeb.org for further details.  LEARN MORE